83 completed, 21 recruiting, 13 active not recruiting, 13 terminated. 153 Phase 2, 35 Phase 1, 5 Phase 3.
Follow Amyloidosis: new trials by email Literature Review of Amyloidosis trials Research Report on Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy GEB-101 Injection - Hereditary Corneal Dystrophy, Corneal Abnormality | Phase 1 / Phase 2 | Not yet recruiting | GenEditBio Limited | 30 | 2026-10-01 | 2026-09-10 |
| A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis FKC289 infusion - Primary Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Fosun Kairos Biotechnology Co., Ltd. | 32 | 2026-08-01 | 2026-08-14 |
| Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis BCMA bispecific - Amyloid Light-chain Amyloidosis | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 64 | 2026-08-01 | 2026-08-05 |
| BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) QLS4131 - AL Amyloidosis | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-07-20 | 2026-08-07 |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis Belantamab mafodotin, Cyclophosphamide, Bortezomib - Amyloidosis | Phase 2 | Recruiting | GlaxoSmithKline | 60 | 2026-06-24 | 2026-11-03 |
| A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). Teclistamab - Multiple Myeloma, AL Amyloidosis | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 30 | 2026-05-22 | 2026-08-03 |
| Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis sonrotoclax, Daratumumab, Dexamethasone - AL Amyloidosis (AL), t(11;14) Positive | Phase 2 | Recruiting | Peking University People's Hospital | 39 | 2026-02-10 | 2026-07-28 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Teclistamab-Daratumumab in AL Amyloidosis Teclistamab, Daratumumab and Hyaluronidase-fihj - Amyloid Light-chain Amyloidosis | Phase 2 | Recruiting | Rajshekhar Chakraborty, MD | 25 | 2025-11-07 | 2026-07-13 |
| Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM ALXN2220 - Amyloid Transthyretin Cardiomyopathy | Phase 2 | Active not recruiting | Neurimmune AG | 35 | 2025-08-28 | 2026-10-07 |
| A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. AZD0120 - Relapsed AL Amyloidosis, Refractory AL Amyloidosis | Phase 1 / Phase 2 | Recruiting | Alexion Pharmaceuticals, Inc. | 91 | 2025-08-18 | 2026-07-02 |
| A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis Teclistamab - AL Amyloidosis | Phase 2 | Active not recruiting | European Myeloma Network B.V. | 30 | 2025-07-02 | 2026-07-20 |
| Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis Eque-cel CAR-T Therapy - AL Amyloidosis | Phase 2 | Not yet recruiting | Nanjing IASO Biotechnology Co., Ltd. | 17 | 2025-07-01 | 2025-07-09 |
| Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis Teclistamab (Tec) - AL Amyloidosis | Phase 2 | Recruiting | Peking Union Medical College Hospital | 35 | 2025-06-28 | 2025-07-23 |
| Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage Colchicine 0.5mg, Matching placebo - Cerebral Amyloid Angiopathy, Intracerebral Hemorrhage Lobar | Phase 2 | Recruiting | Huashan Hospital | 80 | 2025-06-18 | 2025-06-26 |
| 124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome 124I-evuzamitide - Lumbar Spinal Stenosis, Carpal Tunnel Syndrome (CTS) | Phase 2 | Enrolling by invitation | University of Tennessee Graduate School of Medicine | 40 | 2025-05-22 | 2026-07-21 |
| Teclistamab in Previously Treated AL Amyloidosis Teclistamab (Tec) - AL Amyloidosis | Phase 2 | Recruiting | Peking Union Medical College Hospital | 30 | 2025-05-21 | 2025-05-25 |
| Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy XYWAV, gammaCore Sapphire - Cerebral Amyloid Angiopathy | Phase 2 | Enrolling by invitation | Leiden University Medical Center | 60 | 2025-03-27 | 2026-02-24 |
| Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis HBI0101 CART - Multiple Myeloma, Refractory to Standard Treatment, Multiple Myeloma, Relapsed | Phase 2 | Recruiting | Polina Stepensky | 180 | 2025-03-01 | 2026-11-04 |
| Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis Elranatamab - AL Amyloidosis | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 49 | 2024-11-01 | 2026-08-19 |
Showing 20 of 153. Sign in to see all of them.
Immunoglobulin Light-chain Amyloidosis (92) · Multiple Myeloma (45) · Neoplasms, Plasma Cell (23) · Leukemia, Lymphocytic, Chronic, B-Cell (15) · Lymphoma, Mantle-Cell (15) · Burkitt Lymphoma (14) · Hodgkin Disease (14) · Lymphoma, B-Cell, Marginal Zone (14) · Lymphoma, Follicular (14) · Lymphoma, Large B-Cell, Diffuse (14) · Lymphoma, Large-Cell, Immunoblastic (14) · Lymphoma, Non-Hodgkin (14) · Amyloid Neuropathies, Familial (13) · Lymphoma (13)
Metabolic Diseases (153) · Nutritional and Metabolic Diseases (153) · Proteostasis Deficiencies (152) · Immune System Diseases (102) · Immunoproliferative Disorders (101) · Neoplasms (101) · Neoplasms by Histologic Type (101) · Paraproteinemias (98) · Lymphoproliferative Disorders (97) · Neoplasms, Plasma Cell (78) · Cardiovascular Diseases (55) · Vascular Diseases (53) · Hematologic Diseases (48) · Hemic and Lymphatic Diseases (48)
Dexamethasone (42) · Melphalan (21) · Cyclophosphamide (19) · Bortezomib (16) · daratumumab (15) · Calcium Dobesilate (14) · Lenalidomide (12) · Filgrastim (10) · Peripheral Blood Stem Cell Transplantation (10) · pomalidomide (8) · Thalidomide (7) · dexamethasone acetate (6) · birtamimab (5) · ixazomib (5) · Doxycycline (4)
Boston Medical Center (9) · Mayo Clinic (9) · Fondazione IRCCS Policlinico San Matteo di Pavia (6) · Peking Union Medical College Hospital (5) · Brigham and Women's Hospital (4) · Memorial Sloan Kettering Cancer Center (4) · Pfizer (4) · Prothena Biosciences Ltd. (4) · Barbara Ann Karmanos Cancer Institute (3) · Fred Hutchinson Cancer Center (3) · SWOG Cancer Research Network (3) · University of Tennessee Graduate School of Medicine (3) · Alexion Pharmaceuticals, Inc. (2) · Alnylam Pharmaceuticals (2) · Attralus, Inc. (2)
United States (100) · Italy (22) · France (19) · China (15) · United Kingdom (15) · Germany (14) · Spain (12) · Greece (10) · Netherlands (10) · Australia (7) · Canada (7) · Israel (5) · Sweden (5) · Portugal (4) · Argentina (3)
Vaishali Sanchorawala, MD (9) · Anita D'Souza, MD (2) · David C. Seldin, MD, PhD (2) · Heather Landau, MD (2) · Jeff Packman (2) · Jin Lu (2) · Morie A. Gertz, MD (2) · Rajshekhar Chakraborty, MD (2) · Rodney H Falk, MD (2) · Shaji Kumar, M.D. (2) · Alan Solomon, MD (1) · Alfred Chung, MD (1) · Anca Prica, M.D. (1)
PMID 31353964, PMID 32107748, PMID 40226119, PMID 27494299, PMID 29115008, PMID 30558645, PMID 12000194, PMID 15156165, PMID 15308571, PMID 17554116, PMID 19170225, PMID 19498019, PMID 19841031, PMID 20724537, PMID 21562045, PMID 21911655, PMID 22504925, PMID 22517904, PMID 22983583, PMID 23144200, PMID 23974642, PMID 24004667, PMID 24101373, PMID 24368466, PMID 24668858, PMID 25202139, PMID 25974382, PMID 26858336, PMID 27381904, PMID 27872060, PMID 28130212, PMID 28393570, PMID 28522573, PMID 29972757, PMID 30169969, PMID 30219500, PMID 31119947, PMID 31853709, PMID 31978210, PMID 32083996, PMID 32499241, PMID 32529175, PMID 32654156, PMID 32654212, PMID 32833564, PMID 34125267, PMID 34355354, PMID 34786667, PMID 35737873, PMID 35766224
2023 (5), P30CA015083 (4), 2016 (2), 2025 (2), P30CA022453 (2), U10CA032102 (2), 2008 (1), 2009 (1), 2014 (1), 2018 (1), 2019 (1), K23AG026752 (1), K23HL141445 (1), KL2TR001438 (1), N01CM00039 (1)